A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer

Tanyifor M. Tohnya; Sylvia S.W. Ng; William L. Dahut; John J. Wright; Philip M. Arlen; James L. Gulley; Catherine Parker; Jerome Zeldis; William D. Figg

doi:10.3816/CGC.2004.n.006

A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer

Tanyifor M. Tohnya, Sylvia S.W. Ng, William L. Dahut, John J. Wright, Philip M. Arlen, James L. Gulley, Catherine Parker, Jerome Zeldis, William D. Figg^*

^*Corresponding author for this work

Surgery

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Original language	English
Pages (from-to)	241-243
Number of pages	3
Journal	Clinical Prostate Cancer
Volume	2
Issue number	4
DOIs	https://doi.org/10.3816/CGC.2004.n.006
State	Published - Mar 2004

Keywords

Angiogenesis
Human vein endothelial cell proliferation
Pharmacokinetics

Access to Document

10.3816/CGC.2004.n.006

Cite this

@article{a0e2b5e204ad4996bcb09573339b7d82,

title = "A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid{\texttrademark}), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer",

keywords = "Angiogenesis, Human vein endothelial cell proliferation, Pharmacokinetics",

author = "Tohnya, {Tanyifor M.} and Ng, {Sylvia S.W.} and Dahut, {William L.} and Wright, {John J.} and Arlen, {Philip M.} and Gulley, {James L.} and Catherine Parker and Jerome Zeldis and Figg, {William D.}",

note = "Funding Information: 1Clinical Pharmacology Research Core 2Medical Oncology Clinical Research Unit National Cancer Institute/National Institutes of Health, Bethesda, MD 3Celgene Corporation, Warren, NJ Funding Information: Address for correspondence: William D. Figg, Pharm D Clinical Pharmacology Research Unit National Cancer Institute, National Institutes of Health Bldg 10, Room 5A01 9000 Rockville Pike Bethesda, MD 20892 Fax: 301-402-8606 e-mail: [email protected]",

year = "2004",

month = mar,

doi = "10.3816/CGC.2004.n.006",

language = "English",

volume = "2",

pages = "241--243",

journal = "Clinical Prostate Cancer",

issn = "1540-0352",

publisher = "Cancer Information Group, LP",

number = "4",

}

TY - JOUR

T1 - A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer

AU - Tohnya, Tanyifor M.

AU - Ng, Sylvia S.W.

AU - Dahut, William L.

AU - Wright, John J.

AU - Arlen, Philip M.

AU - Gulley, James L.

AU - Parker, Catherine

AU - Zeldis, Jerome

AU - Figg, William D.

N1 - Funding Information: 1Clinical Pharmacology Research Core 2Medical Oncology Clinical Research Unit National Cancer Institute/National Institutes of Health, Bethesda, MD 3Celgene Corporation, Warren, NJ Funding Information: Address for correspondence: William D. Figg, Pharm D Clinical Pharmacology Research Unit National Cancer Institute, National Institutes of Health Bldg 10, Room 5A01 9000 Rockville Pike Bethesda, MD 20892 Fax: 301-402-8606 e-mail: [email protected]

PY - 2004/3

Y1 - 2004/3

KW - Angiogenesis

KW - Human vein endothelial cell proliferation

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=16344362222&partnerID=8YFLogxK

U2 - 10.3816/CGC.2004.n.006

DO - 10.3816/CGC.2004.n.006

M3 - Article

C2 - 15072608

AN - SCOPUS:16344362222

SN - 1540-0352

VL - 2

SP - 241

EP - 243

JO - Clinical Prostate Cancer

JF - Clinical Prostate Cancer

IS - 4

ER -

A Phase I Study of Oral CC-5013 (Lenalidomide, Revlimid™), a Thalidomide Derivative, in Patients with Refractory Metastatic Cancer

Keywords

Access to Document

Fingerprint

Cite this